We are privileged to welcome Professor Dennis M. Black from the University of California, San Francisco (UCSF), as a Plenary Speaker for SSBH 2026. A towering figure in the field of osteoporosis clinical trials, Professor Black has been the lead investigator for several landmark studies that have shaped current treatment guidelines. In this lecture, he will present the transformative findings of the SABRE (Study to Advance BMD as a Regulatory Endpoint) Project. The SABRE project is a monumental effort that addressed a decades-long challenge in drug development: the necessity of long-term fracture trials for new drug approval. By analyzing data from over 160,000 participants across dozens of clinical trials, Professor Black and his team established Bone Mineral Density (BMD) change as a validated surrogate endpoint for fracture risk reduction. This breakthrough led to the historic 2025 FDA qualification of BMD as a primary regulatory endpoint, significantly accelerating the pathway for future osteoporosis therapies. In this session, Professor Black will detail the rigorous statistical framework of SABRE and discuss how these results will catalyze the development of next-generation bone-forming agents and combination therapies.